Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 74,110 Shares of Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 74,110 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the sale, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. This trade represents a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

William Garrett Gray also recently made the following trade(s):

• On Wednesday, December 18th, William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32.

Checkpoint Therapeutics Stock Down 6.8 %

CKPT stock traded down $0.24 during midday trading on Friday, hitting $3.29. 776,516 shares of the company traded hands, compared to its average volume of 891,713. Checkpoint Therapeutics, Inc. has a twelve month low of $1.38 and a twelve month high of $4.50. The stock has a market capitalization of $160.65 million, a price-to-earnings ratio of -1.79 and a beta of 1.36. The business has a 50 day simple moving average of $3.43 and a 200-day simple moving average of $2.98.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Equities research analysts forecast that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CKPT. State Street Corp lifted its position in shares of Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after purchasing an additional 23,000 shares during the last quarter. Geode Capital Management LLC increased its position in Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after buying an additional 124,787 shares during the period. Magnus Financial Group LLC lifted its holdings in shares of Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after buying an additional 4,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Checkpoint Therapeutics by 160.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after acquiring an additional 80,000 shares during the period. Finally, Walleye Capital LLC acquired a new stake in shares of Checkpoint Therapeutics in the third quarter worth $148,000. 22.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on CKPT shares. D. Boral Capital started coverage on shares of Checkpoint Therapeutics in a research report on Monday, January 13th. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Finally, Lake Street Capital raised their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.